On November 25, 2024, fosun pharma repurchased 0.128 million shares of common stock on the Hong Kong Stock Exchange at a repurchase price ranging from HKD 14 to HKD 14.1 per share, for a total price of approximately HKD 1.7958 million. The repurchased shares will be held as inventory and not planned for cancellation. The repurchase authorization was approved on June 26, 2024, with a total authorization of 55.194 million shares. After the repurchase, the total number of issued shares of fosun pharma is 0.546 billion shares, and the number of inventory shares has increased to 0.593 million shares. According to regulations, no new shares can be issued or inventory shares sold within 30 days after the repurchase, with the suspension period ending on December 25, 2024.

On November 25, 2024, fosun pharma repurchased 0.128 million shares of common stock on the Hong Kong Stock Exchange at a repurchase price ranging from HKD 14 to HKD 14.1 per share, for a total price of approximately HKD 1.7958 million. The repurchased shares will be held as inventory and not planned for cancellation. The repurchase authorization was approved on June 26, 2024, with a total authorization of 55.194 million shares. After the repurchase, the total number of issued shares of fosun pharma is 0.546 billion shares, and the number of inventory shares has increased to 0.593 million shares. According to regulations, no new shares can be issued or inventory shares sold within 30 days after the repurchase, with the suspension period ending on December 25, 2024.